Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics (NASDAQ: TVTX) announced that its Board's Compensation Committee granted inducement equity grants to six new employees on November 10, 2024. The grants consist of restricted stock units (RSUs) covering 24,400 shares of common stock. While subject to the company's 2018 Equity Incentive Plan terms, these RSUs were granted outside the plan as employment inducements under Nasdaq Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.
Travere Therapeutics (NASDAQ: TVTX) ha annunciato che il Comitato per la Compensazione del Consiglio ha concesso incentivi azionari a sei nuovi dipendenti il 10 novembre 2024. Gli incentivi consistono in unità azionarie vincolate (RSU) che coprono 24.400 azioni di comune stock. Sebbene siano soggetti ai termini del Piano di Incentivazione Azionaria del 2018 dell'azienda, queste RSU sono state concesse al di fuori del piano come incentivi all'occupazione ai sensi della Regola 5635(c)(4) di Nasdaq. Le RSU matureranno in quattro anni, con il 25% che matura annualmente, a condizione di un'occupazione continuativa.
Travere Therapeutics (NASDAQ: TVTX) anunció que el Comité de Compensación de su Junta otorgó incentivos en acciones a seis nuevos empleados el 10 de noviembre de 2024. Los incentivos consisten en unidades de acciones restringidas (RSU) que cubren 24,400 acciones de acciones comunes. Si bien están sujetos a los términos del Plan de Incentivos en Acciones de 2018 de la empresa, estas RSU se otorgaron fuera del plan como incentivos laborales bajo la Regla 5635(c)(4) de Nasdaq. Las RSU se acumularán durante cuatro años, con un 25% acumulándose anualmente, condicionado a la continuidad del empleo.
Travere Therapeutics (NASDAQ: TVTX)는 이사회의 보상 위원회가 2024년 11월 10일에 새로운 직원 6명에게 유인 주식 보상을 부여했다고 발표했습니다. 이 보상은 24,400주의 보통주를 포함하는 제한된 주식 단위(RSU)로 구성됩니다. 이러한 RSU는 회사의 2018 주식 인센티브 계획의 조건에 따라 부여되었지만, Nasdaq 규칙 5635(c)(4)에 따라 고용 유인으로 계획 외에서 부여되었습니다. RSU는 4년 동안 분할되며, 매년 25%씩 분할되어 고용의 지속성에 따라 받게 됩니다.
Travere Therapeutics (NASDAQ: TVTX) a annoncé que le Comité de Rémunération de son Conseil a accordé des incitations en actions à six nouveaux employés le 10 novembre 2024. Les incitations se composent d'unités d'actions restreintes (RSU) couvrant 24 400 actions d'actions ordinaires. Bien qu'elles soient soumises aux conditions du Plan d'Incentive des Actions de 2018 de l'entreprise, ces RSU ont été attribuées en dehors du plan comme incitations à l'emploi conformément à la règle 5635(c)(4) du Nasdaq. Les RSU vont s'acquérir sur quatre ans, avec 25 % s'acquérant annuellement, sous réserve d'un emploi continu.
Travere Therapeutics (NASDAQ: TVTX) gab bekannt, dass der Vergütungsausschuss des Vorstands am 10. November 2024 Anreize in Form von Aktien an sechs neue Mitarbeiter gewährt hat. Die Anreize bestehen aus beschränkten Aktieneinheiten (RSUs), die 24.400 Aktien des Stammkapitals abdecken. Obwohl sie den Bedingungen des Aktienanreizplans von 2018 des Unternehmens unterliegen, wurden diese RSUs außerhalb des Plans als Anreize für die Beschäftigung gemäß der Nasdaq-Regel 5635(c)(4) gewährt. Die RSUs werden über vier Jahre fällig, wobei 25 % jährlich fällig werden, abhängig von der fortgesetzten Beschäftigung.
- Company maintains ability to attract new talent through equity compensation
- Potential dilution of existing shareholders through issuance of 24,400 new shares
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years, with
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact Info
| Media: 888-969-7879 mediarelations@travere.com | Investors: 888-969-7879 IR@travere.com |
FAQ
How many shares of RSUs did Travere Therapeutics (TVTX) grant in November 2024?
What is the vesting schedule for Travere Therapeutics' (TVTX) November 2024 RSU grants?
Under which rule did Travere Therapeutics (TVTX) issue the November 2024 inducement grants?
